Somewhat Positive Press Coverage Somewhat Unlikely to Affect CytomX Therapeutics (CTMX) Stock Price

Press coverage about CytomX Therapeutics (NASDAQ:CTMX) has been trending somewhat positive on Monday, according to Accern. Accern rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CytomX Therapeutics earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.873518078834 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Several equities research analysts have commented on the stock. Wedbush assumed coverage on shares of CytomX Therapeutics in a research note on Thursday, September 7th. They issued an “outperform” rating and a $26.00 target price for the company. ValuEngine downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday. BidaskClub raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, July 8th. Jefferies Group LLC set a $25.00 target price on shares of CytomX Therapeutics and gave the company a “buy” rating in a research note on Friday, August 25th. Finally, Cann reaffirmed a “hold” rating on shares of CytomX Therapeutics in a research note on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $25.67.

Shares of CytomX Therapeutics (NASDAQ:CTMX) traded up 0.75% during midday trading on Monday, reaching $17.44. 63,596 shares of the company’s stock traded hands. CytomX Therapeutics has a 52-week low of $9.85 and a 52-week high of $20.02. The stock’s market cap is $642.96 million. The stock has a 50-day moving average price of $15.25 and a 200-day moving average price of $15.24.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). The firm had revenue of $8.75 million during the quarter, compared to analyst estimates of $4.95 million. CytomX Therapeutics had a negative return on equity of 84.61% and a negative net margin of 206.33%. Analysts forecast that CytomX Therapeutics will post ($1.49) earnings per share for the current year.

In other news, Director Frederick W. Gluck sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, June 26th. The shares were sold at an average price of $14.61, for a total value of $73,050.00. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Sean A. Mccarthy sold 4,481 shares of the business’s stock in a transaction on Monday, June 26th. The shares were sold at an average price of $15.00, for a total transaction of $67,215.00. Following the transaction, the insider now owns 8,726 shares in the company, valued at approximately $130,890. The disclosure for this sale can be found here. Insiders sold a total of 70,229 shares of company stock worth $1,145,499 in the last 90 days. Corporate insiders own 8.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect CytomX Therapeutics (CTMX) Stock Price” was first published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://transcriptdaily.com/2017/09/18/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cytomx-therapeutics-ctmx-stock-price.html.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Insider Buying and Selling by Quarter for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply